What is HUTCHMED?
HUTCHMED is a commercial-stage biopharmaceutical company dedicated to the discovery and global development of innovative targeted therapies and immunotherapies. Its focus lies in addressing unmet medical needs in oncology and immunology. The company's strategic capital raises suggest a robust pipeline and a clear path toward market commercialization, positioning it as a key player in the competitive landscape of advanced drug development.
How much funding has HUTCHMED raised?
HUTCHMED has raised a total of $300M across 3 funding rounds:
Share Placement
$100M
Share Placement
$100M
Share Placement
$100M
Share Placement (2020): $100M with participation from General Atlantic
Share Placement (2020): $100M led by CPP Investments
Share Placement (2021): $100M supported by Baring Private Equity Asia
Key Investors in HUTCHMED
General Atlantic
General Atlantic is a global growth equity firm that provides capital and strategic support to high-growth companies, with a known focus on sectors including life sciences and healthcare. Their investment in HUTCHMED signals confidence in the company's commercialization strategy and market potential.
CPP Investments
CPP Investments, the investment arm of the Canada Pension Plan, engages in professional investment management across various sectors. Their participation suggests a long-term investment horizon and a belief in HUTCHMED's sustained growth trajectory.
Baring Private Equity Asia
Baring Private Equity Asia (BPEA) is a major private alternative investment firm with a strong focus on the Asia Pacific region, often providing growth capital. Their backing of HUTCHMED indicates a strategic alignment with the company's expansion and development initiatives.
What's next for HUTCHMED?
The substantial enterprise-level funding and recent strategic investment provide HUTCHMED with significant resources to advance its development pipeline and expand its global reach. This capital infusion is expected to accelerate the clinical trials and regulatory submissions for its lead drug candidates. The company's strategic focus on oncology and immunology, coupled with strong financial backing, positions it for continued growth and potential market leadership in innovative therapeutic areas.
See full HUTCHMED company page
